LAEKNA-B (02105): Enrollment Completed for Phase III Clinical Trial (AFFIRM-205) of LAE002 (Afuresertib) in HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Stock News

2025/12/15

LAEKNA-B (02105) announced that the group has completed patient enrollment for the Phase III clinical trial AFFIRM-205, evaluating LAE002 (afuresertib) in combination with fulvestrant for the treatment of HR+/HER2- locally advanced or metastatic breast cancer (LA/mBC) in patients with PIK3CA/AKT1/PTEN genetic alterations.

AFFIRM-205 is a multicenter, randomized, double-blind, placebo-controlled pivotal study designed to assess the antitumor efficacy and safety of the combination therapy. The group aims to release topline data from this Phase III pivotal study in the first half of 2026 and submit a new drug application to China's National Medical Products Administration later that year.

On November 12, 2025, the group entered into an exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. Under the terms of the agreement, Qilu Pharmaceutical obtained exclusive rights to research, develop, and commercialize LAE002 (afuresertib) in China, including the mainland, Hong Kong SAR, Macau SAR, and Taiwan region.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1132712108"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132712108\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132712108?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 08:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132712108","market":"sh","top_or_hot":-1,"title":"LAEKNA-B (02105): Enrollment Completed for Phase III Clinical Trial (AFFIRM-205) of LAE002 (Afuresertib) in HR+/HER2- Locally Advanced or Metastatic Breast Cancer","media":"Stock News","content":"<p>LAEKNA-B (02105) announced that the group has completed patient enrollment for the Phase III clinical trial AFFIRM-205, evaluating LAE002 (afuresertib) in combination with fulvestrant for the treatment of HR+/HER2- locally advanced or metastatic breast cancer (LA/mBC) in patients with PIK3CA/AKT1/PTEN genetic alterations.</p>\n<p>AFFIRM-205 is a multicenter, randomized, double-blind, placebo-controlled pivotal study designed to assess the antitumor efficacy and safety of the combination therapy. The group aims to release topline data from this Phase III pivotal study in the first half of 2026 and submit a new drug application to China's National Medical Products Administration later that year.</p>\n<p>On November 12, 2025, the group entered into an exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. Under the terms of the agreement, Qilu Pharmaceutical obtained exclusive rights to research, develop, and commercialize LAE002 (afuresertib) in China, including the mainland, Hong Kong SAR, Macau SAR, and Taiwan region.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LAEKNA-B (02105): Enrollment Completed for Phase III Clinical Trial (AFFIRM-205) of LAE002 (Afuresertib) in HR+/HER2- Locally Advanced or Metastatic Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLAEKNA-B (02105): Enrollment Completed for Phase III Clinical Trial (AFFIRM-205) of LAE002 (Afuresertib) in HR+/HER2- Locally Advanced or Metastatic Breast Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-12-15 08:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>LAEKNA-B (02105) announced that the group has completed patient enrollment for the Phase III clinical trial AFFIRM-205, evaluating LAE002 (afuresertib) in combination with fulvestrant for the treatment of HR+/HER2- locally advanced or metastatic breast cancer (LA/mBC) in patients with PIK3CA/AKT1/PTEN genetic alterations.</p>\n<p>AFFIRM-205 is a multicenter, randomized, double-blind, placebo-controlled pivotal study designed to assess the antitumor efficacy and safety of the combination therapy. The group aims to release topline data from this Phase III pivotal study in the first half of 2026 and submit a new drug application to China's National Medical Products Administration later that year.</p>\n<p>On November 12, 2025, the group entered into an exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. Under the terms of the agreement, Qilu Pharmaceutical obtained exclusive rights to research, develop, and commercialize LAE002 (afuresertib) in China, including the mainland, Hong Kong SAR, Macau SAR, and Taiwan region.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1132712108","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132712108","pubTimestamp":1765758016,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LAEKNA-B (02105) announced that the group has completed patient enrollment for the Phase III clinical trial AFFIRM-205, evaluating LAE002 (afuresertib) in combination with fulvestrant for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","III":"信息服务","02105":"来凯医药-B","BK4134":"信息科技咨询与其它服务","BK4203":"医疗保健房地产投资信托","HR":"医疗保健房地产信托","BK4225":"医疗保健房地产信托"},"translate_title":"LAEKNA-B（02105）：LAE002（Afuresertib）治疗HR+/HER2-局部晚期或转移性乳腺癌的III期临床试验（AFFIRM-205）已完成入组","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":1,"III":1,"HR":1},"content_text":"LAEKNA-B (02105) announced that the group has completed patient enrollment for the Phase III clinical trial AFFIRM-205, evaluating LAE002 (afuresertib) in combination with fulvestrant for the treatment of HR+/HER2- locally advanced or metastatic breast cancer (LA/mBC) in patients with PIK3CA/AKT1/PTEN genetic alterations.\nAFFIRM-205 is a multicenter, randomized, double-blind, placebo-controlled pivotal study designed to assess the antitumor efficacy and safety of the combination therapy. The group aims to release topline data from this Phase III pivotal study in the first half of 2026 and submit a new drug application to China's National Medical Products Administration later that year.\nOn November 12, 2025, the group entered into an exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. Under the terms of the agreement, Qilu Pharmaceutical obtained exclusive rights to research, develop, and commercialize LAE002 (afuresertib) in China, including the mainland, Hong Kong SAR, Macau SAR, and Taiwan region.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}